The following trials provide information to treat various types of cardiovascular diseases, both for ongoing and completed clinical trials. For more information on this therapy area please click here.
- collapse A randomised, double-blind, placebo-controlled Phase I study to assess the tolerability, safety, pharmacokinetic, and pharmacodynamic properties of AZD6482, alone and co-administered with ASA, after single ascending intravenous doses to healthy male subjects
- collapse A Phase I, Single-centre, Single-blind, Randomised, Placebo-controlled, Single-dose study to Assess the Safety, Tolerability and Pharmacokinetics after Single Ascending Intravenous Doses of AZD2927 in Healthy Male Subjects
- collapse A Multi-Centre, Double-Blind, Randomised, Placebo-Controlled Phase II Study to Assess the Effects on Atrial and Ventricular Refractoriness of an Intravenous Infusion of AZD2927 in Patients Undergoing an Invasive Electrophysiological Procedure
- collapse Cholesterol Goal Attainment rate and its associated factors among dyslipidemic Patients on lipid-lowering drug therapy in Korea (CRESCENDO study)
- collapse Non-interventional study to assess reaching of cholesterol target values in patients treated with HMG-CoA reductase inhibitors in Croatia
- collapse An Epidemiological Study Aimed to Record Standard Daily Practice in Managing Patients With Hypercholesterolemia
- collapse A Randomised, Single-Blind, Placebo-Controlled, Single-Centre, Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Interaction After Single Ascending Oral Doses of AZD6714 in Healthy Male Volunteers and Male Type II Diabetic Patients
- collapse An Open-Label, Randomised, Placebo-Controlled, Two-Way Crossover, Phase I Single Centre Study in Type 2 Diabetes Mellitus Patients Treated with Metformin to Evaluate the Pharmacokinetics and Pharmacodynamics of Warfarin During Co-administration with AZD1656
- collapse A Randomised, open, two-way Cross-over, Phase I Study to Evaluate the Response to Glucagon versus the spontaneous counter-regulatory response in T2DM Patients treated with AZD1656 and Metformin during hypoglycemia
- collapse A Phase I, Multi-center, Open-label, Single Dose Study, to Assess the Pharmacokinetics of AZD1656 and Its Metabolite in Type 2 Diabetes Mellitus Patients With or Without Renal Impairment
